

AMENDMENT UNDER 37 C.F.R. § 1.116
09/744,550

wherein the solvent comprises at least one $-^{17}\text{OH}$ in its chemical structure, and ^{17}O in the $-^{17}\text{OH}$ exerts a relaxation effect on the H proton bonded thereto and the relaxation effect spreads through the exchange of a proton in a vital component of a target organ or tissue of a living body with said H proton bonded to the ^{17}O , thereby enabling detection by nuclear magnetic resonance.

36. (New) A drug composition comprising an active ingredient of at least one medicament selected from the group consisting of therapeutic agents, nutritional tonic agents, infusions and diagnostic agents, dissolved in a solvent,

wherein the solvent comprises at least one $-^{17}\text{OH}$ in its chemical structure, and ^{17}O in the $-^{17}\text{OH}$ exerts a relaxation effect on the H proton bonded thereto and the relaxation effect spreads through the exchange of a proton in a vital component of a target organ or tissue of a living body with said H proton bonded to the ^{17}O , thereby enabling detection by nuclear magnetic resonance; and,

a concentration of the active ingredient in the resulting drug composition is equal to a concentration of the active ingredient in the medicament.

37. (New) The drug composition according to claim 35 or 36, wherein the solvent is an aqueous solvent.

38. (New) The drug composition according to claim 37 wherein the aqueous solvent is water.

39. (New) The drug composition according to claim 35 or 36, wherein the composition contains a material for a drug delivery system.

AMENDMENT UNDER 37 C.F.R. § 1.116
09/744,550

40. (New) A drug composition comprising an active ingredient of at least one medicament selected from the group consisting of therapeutic agents, nutritional tonic agents, infusions and diagnostic agents, dissolved in a solvent,

wherein the active ingredient of the medicament contains a compound comprising at least either one of ^{-14}NH or ^{-33}SH in its chemical structure, and ^{14}N or ^{33}S in the ^{-14}NH or ^{-33}SH exerts a relaxation effect on the H proton bonded thereto and the relaxation effect spreads through the exchange of a proton in a vital component of a target organ or tissue of a living body with said H proton bonded to the ^{-14}N or ^{-33}S , thereby enabling detection by nuclear magnetic resonance.

41. (New) A drug composition comprising an active ingredient of at least one medicament selected from the group consisting of therapeutic agents, nutritional tonic agents, infusions and diagnostic agents, dissolved in a solvent,

wherein the active ingredient of the medicament contains a compound comprising at least either one of ^{-14}NH or ^{-33}SH in its chemical structure, and ^{14}N or ^{33}S in the ^{-14}NH or ^{-33}SH exerts a relaxation effect on the H proton bonded thereto and the relaxation effect spreads through the exchange of a proton in a vital component of a target organ or tissue of a living body with said H proton bonded to the ^{14}N or ^{33}S , thereby enabling detection by nuclear magnetic resonance; and

a concentration of the active ingredient in the resulting drug composition is equal to a concentration of the active ingredient in the medicament.

42. (New) The drug composition according to claim 40 or 41, wherein the compound comprising at least either one of ^{-14}NH or ^{-33}SH in its chemical structure is an amino acid.

AMENDMENT UNDER 37 C.F.R. § 1.116
09/744,550

*B1
Contd*

43. (New) The drug composition according to claim 40 or 41, wherein the composition contains a material for a drug delivery system.
